ISAL 2023 | Single-center study evaluating the outcomes of patients with AML who relapsed after alloSCT
Sylvain Garciaz
• 21 Mar 2023
Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses the results of a single-center study which investigated the outcomes of patients with acute myeloid leukemia (AML) who relapsed after allogeneic stem cell transplantation (alloSCT) and were treated with either intensive or non-intensive salvage therapy. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
